The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination. - Wikidata - wikimedia - TriplyDB

The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.

The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.

http://www.wikidata.org/entity/Q33679221

about

Is there any scientific evidence for the use of glucosamine in the management of human osteoarthritis?Crystalline glucosamine sulfate in the management of knee osteoarthritis: efficacy, safety, and pharmacokinetic properties Nutraceutical Supplements in the Management and Prevention of Osteoarthritis Differentiation of patented crystalline glucosamine sulfate from other glucosamine preparations will optimize osteoarthritis treatment.Quantitation of glucosamine sulfate in plasma by HPLC-MS/MS after administration of powder for oral solution formulation.The effects of three-month oral supplementation with a nutraceutical and exercise on the locomotor pattern of aged horses.Physiological effects of oral glucosamine on joint health: current status and consensus on future research priorities Chondroitin and glucosamine in the management of osteoarthritis: an update.Effects of Glucosamine and Chondroitin Sulfate on Cartilage Metabolism in OA: Outlook on Other Nutrient Partners Especially Omega-3 Fatty Acids Synthesis and characterization of a new Peptide prodrug of glucosamine with enhanced gut permeability.Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations.Glucosamine activates autophagy in vitro and in vivo.Current concepts in osteoarthritis Nutraceuticals in the management of osteoarthritis : a critical review.Chondroprotection and the prevention of osteoarthritis progression of the knee: a systematic review of treatment agents.Chondroitin sulphate: a focus on osteoarthritis.Combined Treatment With Chondroitin Sulfate and Glucosamine Sulfate Shows No Superiority Over Placebo for Reduction of Joint Pain and Functional Impairment in Patients With Knee Osteoarthritis: A Six-Month Multicenter, Randomized, Double-Blind, Plac Glucosamine exposure reduces proteoglycan synthesis in primary human endothelial cells in vitro Inappropriate claims from non-equivalent medications in osteoarthritis: a position paper endorsed by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).

P2860

Q21195259-5BF402A4-3DE0-473E-8752-46692957ECFA Q24630640-F2ABBBB9-C236-4A3E-A680-D0B18F1931AC Q28076979-2D4D1FC2-95BB-4990-9D0E-57B34437652A Q30235140-6E737F96-D3F3-4CF2-A524-C0A8EF0EF019 Q34059484-72D32604-31C0-4FE8-A93D-D763DF7F95C4 Q34369140-367AA2E5-3734-4CEA-959E-742942637FC7 Q34636799-B0ABA296-72D0-418D-88AC-3AC5030F4EA5 Q34655436-64F1FAEC-97B0-41C4-B5C5-D27BBB77507C Q35147261-9711E832-0B33-43A8-9774-6B735922679A Q35632646-285FA8E2-A492-4A8E-AB9A-DBCC057C3EF7 Q36059429-CCF3CD43-F8BD-4FD8-B5D5-339AD0C1E3B8 Q37168084-FF8BE307-321A-41EB-8373-012E2E133C2D Q37389534-124936E0-DE7C-4A8C-9A4A-1BB18095DEE3 Q38047227-BE00CBBE-B30E-4E42-A522-2BB7ADF8689D Q38215383-111C4B56-043F-45A4-AC1F-9D792C05E669 Q38838064-171B3A76-46DF-4CF0-A4FD-D60ACB650A82 Q39539742-CC3ECA68-83BA-467C-9633-76BDBFAD5434 Q41176136-3A6714BF-6648-4BDB-9689-FB80BDEF28E0 Q47816389-E38961F6-BDA3-4F69-9F78-0DEFB7887510

P2860

The human pharmacokinetics of oral ingestion of glucosamine and chondroitin sulfate taken separately or in combination.

http://www.wikidata.org/entity/Q33679221

description

2009 nî lūn-bûn

@nan

2009 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած

@hyw

2009 թվականի նոյեմբերին հրատարակված գիտական հոդված

@hy

2009年の論文

@ja

2009年論文

@yue

2009年論文

@zh-hant

2009年論文

@zh-hk

2009年論文

@zh-mo

2009年論文

@zh-tw

2009年论文

@wuu

name

The human pharmacokinetics of ...... separately or in combination.

@ast

The human pharmacokinetics of ...... separately or in combination.

@en

type

label

The human pharmacokinetics of ...... separately or in combination.

@ast

The human pharmacokinetics of ...... separately or in combination.

@en

prefLabel

The human pharmacokinetics of ...... separately or in combination.

@ast

The human pharmacokinetics of ...... separately or in combination.

@en

P1433

Q33679221-E6F7A986-FF31-4F33-B6BD-C839457C71D0

P1476

Q33679221-72DBE49F-397C-4A21-9211-BECAAA2FA8D4

P2093

Q33679221-0CB83EE0-E34B-44FC-BEA7-3C6B1CB431DC

Q33679221-16176A15-881E-414B-87CC-AF7413B043EB

Q33679221-9F8631F3-0278-429B-AB10-3BB3AF4494ED

Q33679221-B0C3D013-62A8-4424-AE6D-AE4A494FB2C2

Q33679221-B78BAF99-3869-463E-A628-66DA260B9CF9

Q33679221-C6AE1473-C9A9-4104-9234-A4F5AF9FC5CD

Q33679221-E86AFB14-ADF7-4525-BDA8-2EBC480FD403

Q33679221-F9F5E9B1-A674-4B6B-8B16-C0AAA1D359FA

P2860

Q33679221-078134EB-DEF1-4552-BF87-7851D93B4930

Q33679221-0797CF94-0C98-4FBC-AB65-CECD137A4DA1

Q33679221-22A74D4B-6654-4DFF-9EF4-C14B687EDE45

Q33679221-252A991A-2CCD-4113-AC40-3D31180BF20F

Q33679221-25BDDCED-9F68-4A2C-B6C5-2F5D24C334B6

Q33679221-2DC7EF42-9BBD-449A-AFA7-3F881E476835

Q33679221-2E227ABA-28C5-44E5-9E6B-FC17E17FB695

Q33679221-57C1199A-2603-4BE5-B98D-E5569A4554FA

Q33679221-6E3C094B-E1AA-46BB-8882-4E7E1D6520E1

Q33679221-6ECA28DD-833C-4719-9EE9-DDBDE67E326B

P304

Q33679221-7EEA6404-5903-4159-AEA7-8007C0BBD32E

P31

Q33679221-37115A9E-09DF-4C46-B0CC-27C3AE6ECA74

P356

Q33679221-3EBE3762-921A-4AF2-AE78-AA172FA530D1

P433

Q33679221-7ABEE90D-8396-4609-90B6-B063334E37A5

P478

Q33679221-AEE1FBD5-72E9-4ED8-AEA7-7F597C0F8DE9

P577

Q33679221-A90244A3-802D-467B-8DEC-D993C12C0164

P5875

Q33679221-F733B2E4-7762-47FD-AB19-8BBD032B0A42

P698

Q33679221-07481090-C542-4185-A84A-B33BBB52CD5B

P932

Q33679221-0F04F567-6784-49F9-A478-93C013771C1D

P356

J.JOCA.2009.10.013

P1433

Osteoarthritis and Cartilage

P1476

The human pharmacokinetics of ...... separately or in combination.

@en

P2093

A H Plaas

http://www.w3.org/2001/XMLSchema#string

C G Jackson

http://www.w3.org/2001/XMLSchema#string

C Hua

http://www.w3.org/2001/XMLSchema#string

C L Harris

http://www.w3.org/2001/XMLSchema#string

D O Clegg

http://www.w3.org/2001/XMLSchema#string

J D Sandy

http://www.w3.org/2001/XMLSchema#string

J G Barnhill

http://www.w3.org/2001/XMLSchema#string

S Kim-Rolands

http://www.w3.org/2001/XMLSchema#string

P2860

Chondroitin and glucosamine sulfate in combination decrease the pro-resorptive properties of human osteoarthritis subchondral bone osteoblasts: a basic science study

Glucosamine but not ibuprofen alters cartilage turnover in osteoarthritis patients in response to physical training

Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis.

Synovial fluid levels and serum pharmacokinetics in a large animal model following treatment with oral glucosamine at clinically relevant doses.

Synovial and plasma glucosamine concentrations in osteoarthritic patients following oral crystalline glucosamine sulphate at therapeutic dose.

Comparison of pharmacokinetics of glucosamine and synovial fluid levels following administration of glucosamine sulphate or glucosamine hydrochloride.

A review of evidence-based medicine for glucosamine and chondroitin sulfate use in knee osteoarthritis.

A physiological function of serum proteoglycan bikunin: the chondroitin sulfate moiety plays a central role.

Exercise therapy for the management of osteoarthritis of the hip joint: a systematic review

Determinants of self-reported health status in a population-based sample of persons with radiographic knee osteoarthritis.

P304

297-302

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.JOCA.2009.10.013

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

18

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-10T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

38088960

http://www.w3.org/2001/XMLSchema#string

P698

19912983

http://www.w3.org/2001/XMLSchema#string

P932

2826597

http://www.w3.org/2001/XMLSchema#string